Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Int J Mol Sci ; 23(1)2022 Jan 01.
Article in English | MEDLINE | ID: mdl-35008920

ABSTRACT

The objective of the present research was to study the effect of cold shock (3 °C and 6 °C) on fertilized eggs of the sterlet, Acipenser ruthenus L. Cold shock was applied for various durations (30, 60 and 90 min) and the ploidy levels, survival, and genotypes of the treated embryos/larvae were recorded. Analysis of ploidy levels confirmed the presence of diploid, triploid, and mosaic (1n/2n, 2n/3n, and 1n/2n/3n) genotypes in experimental groups, while it was strictly diploid in control groups. Microsatellite genotyping confirmed both the incidence of polyspermy and retention of the 2nd polar body in experimental groups. However, patterns of inheritance in all diploid offspring in experimental and control groups revealed classical Mendelian disomic inheritance. Interestingly, the observed mosaic sterlets had normal morphology and were alive. However, some larvae had abnormal morphology which may be due to haploid syndrome. In all treatment groups (treatments: 3 °C-30 min; 3 °C-60 min; 3 °C-90 min; 6 °C-60 min), where the percentage of polyploid/mosaic larvae were high, the mortality was also high. Whereas, in the control groups (where there were only diploid (2n) larvae), the mortality was relatively low.


Subject(s)
Cold-Shock Response/physiology , Fishes/growth & development , Fishes/genetics , Ploidies , Alleles , Animals , Chromosome Segregation , Embryonic Development , Fishes/embryology , Larva/growth & development , Microsatellite Repeats/genetics , Survival Analysis
2.
MMWR Morb Mortal Wkly Rep ; 70(5152): 1766-1772, 2021 12 31.
Article in English | MEDLINE | ID: mdl-34968374

ABSTRACT

During June 2021, the highly transmissible† B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating strain in the United States. U.S. pediatric COVID-19-related hospitalizations increased during July-August 2021 following emergence of the Delta variant and peaked in September 2021.§ As of May 12, 2021, CDC recommended COVID-19 vaccinations for persons aged ≥12 years,¶ and on November 2, 2021, COVID-19 vaccinations were recommended for persons aged 5-11 years.** To date, clinical signs and symptoms, illness course, and factors contributing to hospitalizations during the period of Delta predominance have not been well described in pediatric patients. CDC partnered with six children's hospitals to review medical record data for patients aged <18 years with COVID-19-related hospitalizations during July-August 2021.†† Among 915 patients identified, 713 (77.9%) were hospitalized for COVID-19 (acute COVID-19 as the primary or contributing reason for hospitalization), 177 (19.3%) had incidental positive SARS-CoV-2 test results (asymptomatic or mild infection unrelated to the reason for hospitalization), and 25 (2.7%) had multisystem inflammatory syndrome in children (MIS-C), a rare but serious inflammatory condition associated with COVID-19.§§ Among the 713 patients hospitalized for COVID-19, 24.7% were aged <1 year, 17.1% were aged 1-4 years, 20.1% were aged 5-11 years, and 38.1% were aged 12-17 years. Approximately two thirds of patients (67.5%) had one or more underlying medical conditions, with obesity being the most common (32.4%); among patients aged 12-17 years, 61.4% had obesity. Among patients hospitalized for COVID-19, 15.8% had a viral coinfection¶¶ (66.4% of whom had respiratory syncytial virus [RSV] infection). Approximately one third (33.9%) of patients aged <5 years hospitalized for COVID-19 had a viral coinfection. Among 272 vaccine-eligible (aged 12-17 years) patients hospitalized for COVID-19, one (0.4%) was fully vaccinated.*** Approximately one half (54.0%) of patients hospitalized for COVID-19 received oxygen support, 29.5% were admitted to the intensive care unit (ICU), and 1.5% died; of those requiring respiratory support, 14.5% required invasive mechanical ventilation (IMV). Among pediatric patients with COVID-19-related hospitalizations, many had severe illness and viral coinfections, and few vaccine-eligible patients hospitalized for COVID-19 were vaccinated, highlighting the importance of vaccination for those aged ≥5 years and other prevention strategies to protect children and adolescents from COVID-19, particularly those with underlying medical conditions.


Subject(s)
COVID-19/therapy , Adolescent , COVID-19/epidemiology , COVID-19 Vaccines/administration & dosage , Child , Child, Preschool , Coinfection/epidemiology , Female , Hospitalization , Hospitals , Humans , Infant , Male , Pediatric Obesity/epidemiology , Treatment Outcome , United States/epidemiology , Vaccination/statistics & numerical data
3.
J Public Health Manag Pract ; 24(5): 440-443, 2018.
Article in English | MEDLINE | ID: mdl-29227417

ABSTRACT

The 2014-2019 Prevention Research Centers (PRC) Program Funding Opportunity Announcement stated that "all applicants will be expected to collaborate with CDC to collect data to be able to perform cost analysis." For the first time in the 30-year history of the PRC Program, a cost indicator was included in the PRC Program Evaluation and a cost analysis (CA) instrument developed. The PRC-CA instrument systematically collects data on the cost of the PRC core research project to eventually answer the CDC PRC Program Evaluation question: "To what extent do investments in PRCs support the scalability, sustainability, and effectiveness of the outcomes resulting from community-engaged efforts to improve public health?" The objective of this article is to briefly describe the development of the PRC-CA instrument. Data obtained from the PRC-CA instrument can be used to generate cost summaries to inform decision making within the PRC Program and each individual PRC.


Subject(s)
Cooperative Behavior , Preventive Medicine/economics , Preventive Medicine/organization & administration , Research/economics , Costs and Cost Analysis , Humans , Preventive Medicine/instrumentation , Program Evaluation/methods , Research/trends
4.
Tuberculosis (Edinb) ; 145: 102479, 2024 03.
Article in English | MEDLINE | ID: mdl-38262199

ABSTRACT

Persistence of Mycobacterium tuberculosis (Mtb) is one of the challenges to successful treatment of tuberculosis (TB). In vitro models of non-replicating Mtb are used to test the efficacy of new molecules against Mtb persisters. The H37Ra strain is attenuated for growth in macrophages and mice. We validated H37Ra-infected immunocompetent mice for testing anti-TB molecules against slow/non-replicating Mtb in vivo. Swiss mice were infected intravenously with H37Ra and monitored for CFU burden and histopathology for a period of 12 weeks. The bacteria multiplied at a slow pace reaching a maximum load of ∼106 in 8-12 weeks depending on the infection dose, accompanied by time and dose-dependent histopathological changes in the lungs. Surprisingly, four-weeks of treatment with isoniazid-rifampicin-ethambutol-pyrazinamide combination caused only 0.4 log10 and 1 log10 reduction in CFUs in lungs and spleen respectively. The results show that ∼40 % of the H37Ra bacilli in lungs are persisters after 4 weeks of anti-TB therapy. Isoniazid/rifampicin monotherapy also showed similar results. A combination of bedaquiline and isoniazid reduced the CFU counts to <200 (limit of detection), compared to ∼5000 CFUs by isoniazid alone. The study demonstrates an in vivo model of Mtb persisters for testing new leads using a BSL-2 strain.


Subject(s)
Mycobacterium tuberculosis , Tuberculosis , Animals , Mice , Isoniazid/pharmacology , Isoniazid/therapeutic use , Rifampin/pharmacology , Rifampin/therapeutic use , Tuberculosis/drug therapy , Tuberculosis/microbiology , Pyrazinamide/therapeutic use , Antitubercular Agents/pharmacology , Antitubercular Agents/therapeutic use
5.
Hosp Pediatr ; 12(9): 760-783, 2022 09 01.
Article in English | MEDLINE | ID: mdl-35670605

ABSTRACT

OBJECTIVES: To describe coronavirus disease 2019 (COVID-19)-related pediatric hospitalizations during a period of B.1.617.2 (Δ) variant predominance and to determine age-specific factors associated with severe illness. METHODS: We abstracted data from medical charts to conduct a cross-sectional study of patients aged <21 years hospitalized at 6 United States children's hospitals from July to August 2021 for COVID-19 or with an incidental positive severe acute respiratory syndrome coronavirus 2 test. Among patients with COVID-19, we assessed factors associated with severe illness by calculating age-stratified prevalence ratios (PR). We defined severe illness as receiving high-flow nasal cannula, positive airway pressure, or invasive mechanical ventilation. RESULTS: Of 947 hospitalized patients, 759 (80.1%) had COVID-19, of whom 287 (37.8%) had severe illness. Factors associated with severe illness included coinfection with respiratory syncytial virus (RSV) (PR 3.64) and bacteria (PR 1.88) in infants; RSV coinfection in patients aged 1 to 4 years (PR 1.96); and obesity in patients aged 5 to 11 (PR 2.20) and 12 to 17 years (PR 2.48). Having ≥2 underlying medical conditions was associated with severe illness in patients aged <1 (PR 1.82), 5 to 11 (PR 3.72), and 12 to 17 years (PR 3.19). CONCLUSIONS: Among patients hospitalized for COVID-19, factors associated with severe illness included RSV coinfection in those aged <5 years, obesity in those aged 5 to 17 years, and other underlying conditions for all age groups <18 years. These findings can inform pediatric practice, risk communication, and prevention strategies, including vaccination against COVID-19.


Subject(s)
COVID-19 , Coinfection , Respiratory Syncytial Virus Infections , COVID-19/epidemiology , COVID-19/therapy , Child , Cross-Sectional Studies , Hospitalization , Humans , Infant , Obesity , Respiratory Syncytial Virus Infections/epidemiology , SARS-CoV-2 , United States/epidemiology
6.
Indian Heart J ; 61(1): 58-60, 2009.
Article in English | MEDLINE | ID: mdl-19729691

ABSTRACT

BACKGROUND AND AIM: The prevalence of congenital heart disease (CHD) is not known in our country. The aim of present study was to find out the prevalence of CHD in school children of eastern Uttar Pradesh. METHOD: A team consisting of a cardiologist, physicians and junior residents visited schools in the area. All the children were examined for presence of cardiac murmur or history of heart disease or any intervention. Those with murmurs or previous history of heart disease were called to the Medical College Hospital for evaluation by ECG, chest X-ray and echocardiography for confirmation of the lesion. RESULTS: Out of 118,212 children examined, 142 were found to have CHD. The prevalence was 1.3 per 1000 children and the commonest lesions were ventricular and atrial septal defects, aortic stenosis with or without regurgitation, and pulmonary stenosis. CONCLUSION: CHD prevalence is 1.3 per 1000 school children that is nearly two and a half times more than that of RHD. Knowing it is important for development of facilities for CHD care in our setup.


Subject(s)
Heart Defects, Congenital/epidemiology , Adolescent , Child , Female , Humans , India/epidemiology , Male , Prevalence , Schools/statistics & numerical data , Students/statistics & numerical data
7.
Tuberculosis (Edinb) ; 115: 89-95, 2019 03.
Article in English | MEDLINE | ID: mdl-30948182

ABSTRACT

Persisters of Mycobacterium tuberculosis (Mtb) that fail to form colonies on agar media when de-stressed are termed as differentially detectable (DD) persisters. Since in the host, Mtb primarily survives by utilizing lipids, we used a long-term lipid diet model to induce DD persisters of M. tuberculosis. Persisters were induced by replacing the dextrose-containing medium with one containing fatty acids instead of dextrose (FAM). After 2, 4 or 6 weeks, CFU and most probable number assays were performed; the difference between the two gave an estimate of DD persisters. Since rifampicin has been shown to induce formation of DD persisters in vitro, one set of FAM cultures were also given short-term rifampicin stress after 2, 4 or 6 weeks. Fraction of DD persisters increased with time and rifampicin treatment enhanced the effect of fatty acids, at 2 and 4 weeks. At six weeks, even in the absence of rifampicin, ∼95% population were DD persisters. The DD persisters were vulnerable to drugs interfering with bacterial respiration such as thioridazine, bedaquiline and clofazimine. The study indicates potential formation of DD persisters of Mtb in a lipid-rich microenvironment in the host even before antibiotic therapy.


Subject(s)
Antitubercular Agents/pharmacology , Lipids/pharmacology , Mycobacterium tuberculosis/drug effects , Culture Media , Fatty Acids/pharmacology , Microbial Sensitivity Tests , Models, Biological , Phenotype , Tuberculosis, Multidrug-Resistant/drug therapy
9.
Indian Heart J ; 59(1): 42-3, 2007.
Article in English | MEDLINE | ID: mdl-19098335

ABSTRACT

BACKGROUND: Rheumatic heart disease is a major health problem in our country. There is evidence from South India that its prevalence is declining. This study attempts to confirm whether this is so in North India as well. METHODS AND RESULTS: A total of 118,212 (68,357 males, 49,855 females) schoolchildren in the age group of 4-18 years were examined for the presence of heart disease. Evaluation, including echocardiography, confirmed that of a total of 389 suspected to have heart disease, 61 had rheumatic heart disease. Thus, the prevalence of rheumatic heart disease was found to be approximately 0.5 per 1000 children. CONCLUSION: In a fairly large school survey conducted by us, the prevalence of rheumatic heart disease turned out to be approximately 0.5 per 1000 children. This is the lowest figure reported from our country so far and confirms the decline of this disease in our country.


Subject(s)
Rheumatic Heart Disease/epidemiology , Adolescent , Child , Child, Preschool , Echocardiography , Female , Humans , India/epidemiology , Male , Prevalence , Rheumatic Heart Disease/diagnostic imaging , Risk Factors
10.
Tuberculosis (Edinb) ; 104: 8-19, 2017 05.
Article in English | MEDLINE | ID: mdl-28454654

ABSTRACT

Triacylglycerol (TAG) is important to mycobacteria both as cell envelope component and energy reservoir. Mycobacterium tuberculosis (Mtb) genome encodes at least 15 putative TAG synthase (tgs)s. We report that one of these genes, Rv3371, specific to pathogenic mycobacteria, when expressed in M. smegmatis leads to modifications in colony morphotype, bacterial architecture, cell surface properties and elevated TAG levels. Rv3371 was found to largely localize in the cell membrane. The Rv3371 promoter is minimally active during exponential growth in vitro, however, is up-regulated under stationary phase, hypoxia, nutrient starvation, nitrosative stress, low iron, in IFN-γ activated macrophages and infected mice. The low iron-induced expression of Rv3371 is likely due to the de-repression by Rv1404, which is probably activated by ideR. An Rv3371 deletion mutant of Mtb showed impaired non-replicating persistence in vitro and altered sensitivity to anti-mycobacterial drugs. In low iron medium, the Rv3371 deletion mutant showed reduced formation of TAG containing extracellular vesicles. Therefore Rv3371 is likely involved in Mtb growth arrest and cell wall alterations during persistence.


Subject(s)
Bacterial Proteins/metabolism , Cell Wall/enzymology , Diacylglycerol O-Acyltransferase/metabolism , Mycobacterium tuberculosis/enzymology , Mycobacterium tuberculosis/growth & development , Stress, Physiological , Triglycerides/metabolism , Animals , Antitubercular Agents/pharmacology , Bacterial Proteins/genetics , Diacylglycerol O-Acyltransferase/genetics , Disease Models, Animal , Female , Gene Expression Regulation, Bacterial , Gene Expression Regulation, Enzymologic , Humans , Mice , Mycobacterium smegmatis/enzymology , Mycobacterium smegmatis/genetics , Mycobacterium smegmatis/growth & development , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/genetics , Promoter Regions, Genetic , Sequence Deletion , THP-1 Cells , Time Factors , Transcription, Genetic , Tuberculosis/microbiology
11.
J Environ Sci Eng ; 54(3): 436-40, 2012 Jul.
Article in English | MEDLINE | ID: mdl-24749207

ABSTRACT

An experiment was conducted in three different tanks for 45 days (T1, T2 and T3) to investigate the effect of dietary Spirulina level on growth and chemical composition of carcass in rohu, Labeo rohita. A diet having de-oiled rice bran(30%), rice polish (15%), de-oiled mustard oil cake(25%), Soya bean oil cake(10%) and de-oiled groundnut cake(20%) was provided to the control (i.e. 100% formulated feed), whereas in T2 95% formulated feed with 5% Spirulina and in T3 90% formulated feed with 10% Spirulina. Data were analysed with ANOVA (P < 0.05) and found significant. There was significant difference in the average final weight of the fish among treatments with highest in the T3 (11.28g) followed by T2 (8.32g) and T1 (7.51g). The higher SGR was recorded in T3 (2.17) followed by T2 (1.52) and T1 (1.28). There was significant difference in the average carcass composition of the fish among treatments with highest level in T3 followed by T2 and T1.


Subject(s)
Aquaculture/methods , Cyprinidae/physiology , Animal Feed/analysis , Animals , Body Weight , Cyprinidae/growth & development , Diet/veterinary , Dose-Response Relationship, Drug , Spirulina
12.
Genet Epidemiol ; 28(2): 110-22, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15578751

ABSTRACT

Related individuals collected for use in linkage studies may be used in case-control linkage disequilibrium analysis, provided one takes into account correlations between individuals due to identity-by-descent (IBD) sharing. We account for these correlations by calculating a weight for each individual. The weights are used in constructing a composite likelihood, which is maximized iteratively to form likelihood ratio tests for single-marker and haplotypic associations. The method scales well with increasing pedigree size and complexity, and is applicable to both autosomal and X chromosomes. We apply the approach to an analysis of association between type 2 diabetes and single-nucleotide polymorphism markers in the PPAR-gamma gene. Simulated data are used to check validity of the test and examine power. Analysis of related cases has better power than analysis of population-based cases because of the increased frequencies of disease-susceptibility alleles in pedigrees with multiple cases compared to the frequencies of these alleles in population-based cases. Also, utilizing all cases in a pedigree rather than just one per pedigree improves power by increasing the effective sample size. We demonstrate that our method has power at least as great as that of several competing methods, while offering advantages in the ability to handle missing data and perform haplotypic analysis.


Subject(s)
Diabetes Mellitus, Type 2/genetics , Models, Genetic , Pedigree , Polymorphism, Single Nucleotide , Alleles , Case-Control Studies , Chromosome Mapping , Genotype , Haplotypes , Humans , Linkage Disequilibrium
SELECTION OF CITATIONS
SEARCH DETAIL